Model input | References | |
---|---|---|
Annual Progressio | ||
Well to hrHPV infection | 4.2% | Kulasingam et al. (2011) [10] |
Progression from hrHPV (12 types) | ||
to CIN1 | 8.1% | Kulasingam et al. (2011) [10]; Insinga RP et al. (2007) [11] |
to CIN2 | 0.1% | Khan MJ et al. (2005) [12] |
to CIN3 | 0.1% | |
Progression from hrHPV 16/18 | ||
to CIN1 | 9.9% | Insinga RP et al. (2007) [11]; Insinga RP et al. (2009) [13] |
to CIN2 | 0.6% | Khan MJ et al. (2005) [12] |
to CIN3 | 1.5% | |
Progression from CIN1 | ||
to CIN2 | 3.2% | Weighted average: Kataja V et al. (1989) [14]; Holowaty P et al. (1999) [15]; Matsumoto K et al. (2006) [16]; Omori M et al. (2007) [17]; Guedes AC et al. (2010) [18] |
to CIN3 | 0.9% | |
to CxCa | 0.3% | |
Progression from CIN2 | ||
to CIN3 | 4.2% | Weighted average: Kataja V et al. (1989) [14]; Holowaty P et al. (1999) [15]; Matsumoto K et al. (2006) [16]; Omori M et al. (2007) [17]; Guedes AC et al. (2010) [18] |
to CxCa | 1.8% | |
CIN3 to CxCa | 3.4% | Weighted average: Kataja V et al. (1989) [14]; Holowaty P et al. (1999) [15]; McCredie et al. (2008) [19] |
Annual mortality rate for CxCa | 0.6% | SEER data. 5 year survival of 68% converted to annual mortality rate [20] |
Annual Regression | ||
Regression from hrHPV (12 types) | ||
with normal cytology to well | 58.6% | Bulkmans NJ et al. (2007) [21] |
with borderline/mild cytology to well | 45.6% | |
Regression from hrHPV 16/18 | ||
with normal cytology to well | 43.8% | Bulkmans NJ et al. (2007) [21] |
with borderline/mild cytology to well | 21.8% | |
Regression from CIN1 | ||
to well | 21.2% | Weighted average: Kataja V et al. (1989) [14]; Holowaty P et al. (1999) [15]; Matsumoto K et al. (2010) [22] |
to hrHPV | 2.4% | |
Regression from CIN2 | ||
to well | 9.4% | Weighted average: Kataja V et al. (1989) [14]; Meyskens FL Jr. et al. (1994) [23]; Holowaty P et al. (1999) [15]; Matsumoto K et al. (2006) [16]; Omori M et al. (2007) [17]; Castle PE et al. (2009) [24]; Guedes AC et al. (2010) [18] |
to CIN1 | 9.4% | |
Regression from CIN3 | ||
to well | 3.9% | Weighted average: Kataja V et al. (1989) [14]; McCredie et al. (2008) [19] |
to CIN1 | 1.6% |